Host-cell reactivation of cis-diamminedichloroplatinum(II)-treated SV40 DNA in normal human, Fanconi anaemia and xeroderma pigmentosum fibroblasts.
Cell survival after treatment with cis-diamminedichloroplatinum(II) [cis-Pt(II)] and host-cell reactivation of cis-Pt(II)-treated SV40 DNA were investigated using two Fanconi anaemia, one xeroderma pigmentosum of complementation group A, and three normal human control fibroblast cell strains. The Fanconi anaemia and xeroderma pigmentosum cell strains showed an increased sensitivity to the cytotoxic action of cis-Pt(II) treatment, suggesting a deficiency in the repair pathway of cis-Pt(II)-induced damage. In addition, the survival of cis-Pt(II)-treated SV40 DNA was about 2-fold lower in xeroderma pigmentosum cells than in control cells. No difference in viral DNA survival was found between Fanconi anaemia and control cells, although the Fanconi anaemia cells were more sensitive to the cytotoxic action of treatment with cis-Pt(II) than the xeroderma pigmentosum cells in the clonogenic cell survival assay.
D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002472:Cell Transformation, Viral / Q000187:drug effects*; D002945:Cisplatin / Q000494:pharmacology*; D004260:DNA Repair; D004279:DNA, Viral / Q000235:genetics*; D005199:Fanconi Anemia / Q000473:pathology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D006801:Humans; D013539:Simian virus 40 / Q000235:genetics*; D012867:Skin / Q000166:cytology; D014983:Xeroderma Pigmentosum / Q000473:pathology
D004279:DNA, Viral; D002945:Cisplatin